公开(公告)号：US06548082B1

公开(公告)日：2003-04-15

申请号：US09515407

申请日：2000-02-29

Applicant: Paul D. Rubin ,  Timothy J. Barberich

Inventor： Paul D. Rubin ,  Timothy J. Barberich

IPC: A61K920

CPC classification number: A61K31/415 ,  A61K31/4178 ,  A61K31/00 ,  A61K2300/00

Abstract: Methods for the treatment, management, or prevention of apnea and apnea disorders, or symptoms thereof, using a therapeutically effective amount of substantially optically pure R(+) ondansetron, or a pharmaceutically acceptable salt thereof, substantially free of its S(−) stereoisomer.

公开(公告)号：US06384038B1

公开(公告)日：2002-05-07

申请号：US09059571

申请日：1998-04-14

Applicant: Paul D. Rubin

Inventor： Paul D. Rubin

IPC: A61K31495

CPC classification number: A61K45/06 ,  A61K31/495 ,  Y10S514/826 ,  Y10S514/849 ,  Y10S514/85 ,  Y10S514/853 ,  Y10S514/86 ,  Y10S514/862 ,  Y10S514/887 ,  A61K31/475 ,  A61K31/47 ,  A61K31/41 ,  A61K31/405 ,  A61K31/40 ,  A61K2300/00

Abstract: Methods and pharmaceutical compositions employing (+) cetirizine, (−) cetirizine, or racemic cetirizine, or a pharmaceutically acceptable salt thereof, and a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof, or decongestant for the treatment, management, and/or prevention of inflammation, asthma or symptoms thereof, allergic disorders such as allergic rhinitis, and dermatitis.

Abstract translation: 使用（+）西替利嗪，（ - ）西替利嗪或外消旋西替利嗪或其药学上可接受的盐和白三烯抑制剂或其药学上可接受的盐，或用于治疗，管理和/或预防的减充血剂的方法和药物组合物 炎症，哮喘或其症状，过敏性疾病如过敏性鼻炎和皮炎。

公开(公告)号：US06174902B1

公开(公告)日：2001-01-16

申请号：US09301196

申请日：1999-04-28

Applicant: William E. Yelle ,  Paul D. Rubin ,  Patrick Koch

Inventor： William E. Yelle ,  Paul D. Rubin ,  Patrick Koch

IPC: A61K4340

CPC classification number: A61K9/1652 ,  A61K9/1611 ,  A61K9/2009 ,  A61K9/2018 ,  A61K9/5026 ,  A61K31/4439

Abstract: Methods and compositions are disclosed utilizing optically pure (+) rabeprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of rabeprazole. The optically pure (+) isomer is also useful for the treatment of gastroesophageal reflux. (+) Rabeprazole is an inhibitor of H+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

Abstract translation: 公开了使用光学纯（+）雷贝拉唑治疗人类溃疡的方法和组合物，同时显着降低与雷贝拉唑的外消旋混合物相关的副作用的伴随的责任。 光学纯的（+）异构体也可用于治疗胃食管反流。 （+）雷贝拉唑是H +释放的抑制剂，因此可用于治疗与胃分泌异常有关的其他病症，如Zollinger-Ellison综合征。

公开(公告)号：US6054463A

公开(公告)日：2000-04-25

申请号：US271269

申请日：1999-03-17

Applicant: Dean A. Handley ,  Paul D. Rubin

Inventor： Dean A. Handley ,  Paul D. Rubin

IPC: A61K31/445 ,  A61K31/4545 ,  A61K45/06 ,  A61P11/06 ,  A61P37/08 ,  A61P43/00 ,  A61K31/44

CPC classification number: A61K45/06 ,  A61K31/445 ,  A61K31/4545 ,  Y10S514/826 ,  Y10S514/864

Abstract: The invention relates to methods of utilizing descarboethoxyloratadine ("DCL") for the treatment of dermatitis. The invention also encompasses the topical administration of descarboethoxyloratadine using various dosage forms for the treatment of dermatitis.

Abstract translation: 本发明涉及利用去甲氧基吡咯烷（“DCL”）用于治疗皮炎的方法。 本发明还包括使用用于治疗皮炎的各种剂型的外消旋乙氧基吗啡啶的局部施用。

公开(公告)号：US07030142B1

公开(公告)日：2006-04-18

申请号：US09527844

申请日：2000-03-17

Applicant: Timothy J. Barberich ,  Paul D. Rubin ,  William E. Yelle

Inventor： Timothy J. Barberich ,  Paul D. Rubin ,  William E. Yelle

IPC: A01N43/60 ,  A61K31/495

CPC classification number: A61K31/495

Abstract: The invention relates to novel methods using, and pharmaceutical compositions comprising, ziprasidone metabolites. The methods and compositions of the invention are suitable for the treatment of neuroleptic and related disorders. The invention further encompasses methods of preparing ziprasidone sulfoxide and ziprasidone sulfone.

Abstract translation: 本发明涉及使用包含齐拉西酮代谢物的药物组合物的新方法。 本发明的方法和组合物适用于治疗精神安定药和相关疾病。 本发明还包括制备齐拉西酮亚砜和齐拉西酮砜的方法。

公开(公告)号：US06790849B2

公开(公告)日：2004-09-14

申请号：US10105331

申请日：2002-03-26

Applicant: Paul D. Rubin

Inventor： Paul D. Rubin

IPC: A61K314965

CPC classification number: A61K45/06 ,  A61K31/495 ,  Y10S514/826 ,  Y10S514/849 ,  Y10S514/85 ,  Y10S514/853 ,  Y10S514/86 ,  Y10S514/862 ,  Y10S514/887 ,  A61K31/475 ,  A61K31/47 ,  A61K31/41 ,  A61K31/405 ,  A61K31/40 ,  A61K2300/00

Abstract: Methods and pharmaceutical compositions employing (+) cetirizine, (−) cetirizine, or racemic cetirizine, or a pharmaceutically acceptable salt thereof, and a leukotriene inhibitor, or a pharmaceutically acceptable salt thereof, or decongestant for the treatment, management, and/or prevention of inflammation, asthma or symptoms thereof, allergic disorders such as allergic rhinitis, and dermatitis.

Abstract translation: 使用（+）西替利嗪，（ - ）西替利嗪或外消旋西替利嗪或其药学上可接受的盐和白三烯抑制剂或其药学上可接受的盐，或用于治疗，管理和/或预防的减充血剂的方法和药物组合物 炎症，哮喘或其症状，过敏性疾病如过敏性鼻炎和皮炎。

公开(公告)号：US06552045B2

公开(公告)日：2003-04-22

申请号：US10041479

申请日：2002-01-10

Applicant: Paul D. Rubin ,  Timothy J. Barberich

Inventor： Paul D. Rubin ,  Timothy J. Barberich

IPC: A61K31445

CPC classification number: A61K31/135 ,  A61K31/415 ,  A61K31/445 ,  A61K38/16 ,  A61K45/06 ,  A61K2300/00

Abstract: The invention relates to methods and compositions for the prevention, treatment, or management of gastrointestinal disorders or symptoms thereof, employing two or more agents or compounds to provide a triple site action on 5-HT3 receptors, 5-HT4 receptors, and at least one of H2 receptors and proton pumps.

公开(公告)号：US06506753B2

公开(公告)日：2003-01-14

申请号：US09877103

申请日：2001-06-11

Applicant: Thomas P. Jerussi ,  Chrisantha H. Senanayake ,  Paul D. Rubin ,  Yaping Hong ,  Roger A. Bakale ,  Tingjian Xiang ,  Fran A. McConville

Inventor： Thomas P. Jerussi ,  Chrisantha H. Senanayake ,  Paul D. Rubin ,  Yaping Hong ,  Roger A. Bakale ,  Tingjian Xiang ,  Fran A. McConville

IPC: A61K3150

CPC classification number: A61K31/4985 ,  A61K31/498 ,  C07B2200/07 ,  C07D487/04

Abstract: The invention is directed to compositions comprising, and methods of using, racemic N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (−)-N-desmethylzopiclone in the treatment and prevention of diseases and conditions in mammals. The invention is further directed to novel methods of preparing N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (−)-N-desmethylzopiclone.

公开(公告)号：US06495605B2

公开(公告)日：2002-12-17

申请号：US09803956

申请日：2001-03-13

Applicant: John R. McCullough ,  Paul D. Rubin

Inventor： John R. McCullough ,  Paul D. Rubin

IPC: A01N3302

CPC classification number: A61K31/137 ,  A61K9/2018 ,  A61K9/2059 ,  A61K31/135

Abstract: Methods and compositions are disclosed utilizing the optically pure (+)-isomer of bupropion to assist in smoking cessation, for treating smoking and nicotine addiction, and for treating pain, including, but not limited to, chronic pain, neuropathetic pain and reflex sympathetic dystrophy, and other disorders such as narcolepsy, chronic fatigue syndrome, fibromyalgia, seasonal affective disorder and premenstrual syndrome, while avoiding adverse affects associated with racemic bupropion.

Abstract translation: 公开利用安非他酮的光学纯的（+）异构体来帮助戒烟，治疗吸烟和尼古丁成瘾以及治疗疼痛的方法和组合物，包括但不限于慢性疼痛，神经性疼痛和反射性交感神经营养不良 ，以及其他疾病如发作性睡病，慢性疲劳综合征，纤维肌痛，季节性情感障碍和经前期综合征，同时避免与外消旋安非他酮相关的不良影响。

公开(公告)号：US06465470B2

公开(公告)日：2002-10-15

申请号：US09988935

申请日：2001-11-19

Applicant: Timothy J. Barberich ,  Paul D. Rubin ,  William E. Yelle

Inventor： Timothy J. Barberich ,  Paul D. Rubin ,  William E. Yelle

IPC: A61K3150

CPC classification number: A61K31/496 ,  C07D249/12

Abstract: The R-isomer of the hydroxy metabolite of nefazodone, R-hydroxynefazodone, is an effective treatment for depression which does not give rise to the adverse effects associated with nefazodone. R-hydroxynefazodone is also useful in the treatment of migraine headaches, panic disorders, post traumatic stress disorder and sleep disorders.